AMGN · News · 20260909N

IMDELLTRA Lung Cancer Results

AMGEN INC · 2026-09-09 · Importance 52 · Surprise 42

On September 9, 2026, Amgen and AstraZeneca reported that a late-stage study of Imdelltra plus Imfinzi improved overall survival, progression-free survival, and response rates in patients with extensive-stage small-cell lung cancer. The combination did not identify new safety concerns. Imdelltra had generated $513 million in sales in the prior year, exceeding the company’s $302 million materiality threshold, and received accelerated and traditional U.S. FDA approvals in 2024 and 2025, respectively.

Key facts

• A late-stage clinical trial of the combination of Amgen's Imdelltra and AstraZeneca's Imfinzi showed improved overall survival in patients with extensive-stage small-cell lung cancer. source
• The Imdelltra plus Imfinzi combination showed improved progression-free survival in patients with extensive-stage small-cell lung cancer. source
• The Imdelltra plus Imfinzi combination showed improved response rates in patients with extensive-stage small-cell lung cancer. source
• The late-stage trial of the Imdelltra and Imfinzi combination identified no new safety concerns. source
• Imdelltra received accelerated FDA approval in 2024 and traditional FDA approval in 2025. source
• MarketBeat reported that despite a "Hold" consensus rating from analysts, Amgen had positive Phase 3 results for one of its oncology drugs. source